Schiff bases derived from p-aminobenzyl alcohol as trigger groups for pH-dependent prodrug activation
摘要:
A number of novel acid-sensitive Schiff bases derived horn p-aminobenzyl alcohol and various benzaldehyde derivatives were synthesized and were subsequently shown to trigger benzyl elimination reactions The kinetics of acid-catalyzed hydiolysis at pH 50 as well as stability at pH 74 were studied using fluorogenic model compounds Two fluoro-substituted Schiff bases showed efficient hydrolysis at pH 5 0 combined with a long-term stability at pH 74 and are considered suitable candidates for the development of anticancer prodrugs (c) 2010 Elsevier Ltd All lights reserved
Schiff bases derived from p-aminobenzyl alcohol as trigger groups for pH-dependent prodrug activation
摘要:
A number of novel acid-sensitive Schiff bases derived horn p-aminobenzyl alcohol and various benzaldehyde derivatives were synthesized and were subsequently shown to trigger benzyl elimination reactions The kinetics of acid-catalyzed hydiolysis at pH 50 as well as stability at pH 74 were studied using fluorogenic model compounds Two fluoro-substituted Schiff bases showed efficient hydrolysis at pH 5 0 combined with a long-term stability at pH 74 and are considered suitable candidates for the development of anticancer prodrugs (c) 2010 Elsevier Ltd All lights reserved
Schiff bases derived from p-aminobenzyl alcohol as trigger groups for pH-dependent prodrug activation
作者:Ivonne A. Müller、Felix Kratz、Manfred Jung、André Warnecke
DOI:10.1016/j.tetlet.2010.06.055
日期:2010.8
A number of novel acid-sensitive Schiff bases derived horn p-aminobenzyl alcohol and various benzaldehyde derivatives were synthesized and were subsequently shown to trigger benzyl elimination reactions The kinetics of acid-catalyzed hydiolysis at pH 50 as well as stability at pH 74 were studied using fluorogenic model compounds Two fluoro-substituted Schiff bases showed efficient hydrolysis at pH 5 0 combined with a long-term stability at pH 74 and are considered suitable candidates for the development of anticancer prodrugs (c) 2010 Elsevier Ltd All lights reserved